Aytu BioPharma, Inc.
Nasdaq: AYTU

October 2023

Forward Looking Statements

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as "may," "will," "should," "forecast," "could," "expect," "suggest," "believe," "estimate," "continue," "anticipate," "intend," "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others, risks associated with: the Company's plans relating to the Company's overall financial and operational performance, the Company's commercial performance, regulatory status, reimbursement status, and other factors affecting their commercial uptake, clinical development and commercialization of the Company's current and future development assets, the anticipated start dates, durations and completion dates, as well as the potential future results of the Company's ongoing and future clinical trials, the anticipated designs of the Company's future clinical trials, and the anticipated future regulatory submissions, potential adverse changes to the Company's financial position or business plans, the results of operations, strategy and plans, changes in capital markets and the ability of the Company to finance operations in the manner expected, risks relating to gaining market acceptance of the Company's products, risks related to the ongoing COVID-19 pandemic and its impact on the Company's operations, the Company's ability to effectively integrate operations and manage integration costs following the Company's recent acquisitions, the Company's partners performing their required activities, the Company's anticipated future cash position, regulatory and compliance challenges and future events under current and potential future collaboration. Additional risks are described in "Risk Factors" in Part I, Item 1A of Aytu's most recent Annual Report on Form 10-K and in the other reports and documents it files with the Securities and Exchange Commission.

Company Overview

Commercial stage pharmaceutical company providing ADHD and pediatric-focused prescription drugs.

Strong Revenue Growth

- FY 2023 (Jun) total net revenue increased 11% to $107.4 million from $96.7 million in year ago period.
- FY 2023 (Jun) Rx Segment net revenue was $73.8 million, compared to $61.1 million last year, growth of 21%.

Positive Adjusted EBITDA for Rx Segment

- FY 2023 (Jun) Rx Segment Adjusted EBITDA was a positive $9.4 million.
- Pipeline R&D, which contributed a $(2.6) million to Adjusted EBITDA during FY 2023 (Jun) has since been suspended.
- Record Q4 (Jun) 2023 prescription trends of up 32% across ADHD and pediatric portfolios driving revenue growth

Market Dynamics and Company Growth Drivers

- Ongoing shortages of ADHD simulants continued into 2023 and include generic Adderall XD and Concerta, presenting an opportunity for Adzenys XR-ODT and Cotempla XR-ODT which are bioequivalent to Adderall XR and methylphenidate ER.
- Aytu RxConnect, a best-in-class patient access program that enables affordable, predictable, hassle-free patient access to Aytu Rx products to drive patient adherence and increased pull-through of Rx brands.

Strong Revenue Growth

Revenue

June 30 Fiscal Year-End



Strategic Realignment to Focus on Profitable, Growing Rx Segment

Aytu generated positive Adjusted EBITDA in FY 2023

- Q4 2023 Rx Adjusted EBITDA was positive $8.3 million
  - EBITDA margin of 35%
- FY 2023 (June) Rx Adjusted EBITDA was positive $9.4 million
- During fiscal 2023 Aytu announced strategic shifts to focus corporate resources on Rx commercial segment
  - Indefinite suspension of all clinical development programs
  - Wind down or sale of Consumer Health segment
- Expected to significantly enhance cash flows
- $23.0 million cash on hand as of June 30, 2023

Aytu BioPharma's Value Drivers

Growth Drivers

- Ramping prescription & revenue growth driven by organic sales and internal programs
  - Overall net revenue from prescription products was $73.8 million in FY 2023, compared to $61.1 million in the prior year period, growth of 21%.
  - ADHD products grew 9% YoY
  - Pediatric products grew 58% YoY
- Emphasis on ADHD and pediatric medicines, with novel, IP-protected brands competing in large therapeutic categories
- Growth driven by leveraging the Aytu RxConnect platform, new product launches and salesforce effectiveness

Profitability Improvements

- Manufacturing transfer of ADHD medicines underway:
  - Gross Margin improvement
  - Adzenys Post Approval Supplement (PAS) approved April 2023
  - Cotempla PAS submitted July 2023
  - Reduction of manufacturing facility footprint in May 2023
- Continuing reductions in operating expenses
- Rx Segment → Positive Adjusted EBITDA[1] for fiscal year 2023
- Rx Segment → 35% EBITDA margin (Q4 FY23)

1. Aytu uses the term EBITDA, which is a term not defined under United States Generally Accepted Accounting Principles. The Company uses this term because it is a widely accepted financial indicator utilized to analyze and compare companies on the basis of operating performance. The Company believes that presenting EBITDA by segments allows investors to evaluate the various performance of these segments. The Company's method of computation of adjusted EBITDA may or may not be comparable to other similarly titled measures used by other companies. We believe that net loss is the performance measure calculated and presented in accordance with U.S. GAAP that is most directly comparable to EBITDA.

Rx Segment Overview

Differentiated Rx Brands Focused on ADHD & Pediatrics

Net revenue from Rx products was $73.8 million in FY 2023, compared to $61.1 million in FY 2022, growth of 21% driven by organic growth and acquisitions.

Adzenys XR-ODT®
(amphetamine) Extended-Release Orally Disintegrating Tablets 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg

Novel, Effective, Extended-Release ADHD Treatment

- Only FDA-approved, extended-release, orally-disintegrating amphetamine tablet
- Effective, consistent treatment lasting over twelve hours
- Adderall XR shortages creates potential short-term growth opportunity. Adzenys XR-ODT is bioequivalent to Adderall XR.

Cotempla XR-ODT®
(methylphenidate) Extended-Release Orally Disintegrating Tablets 8.6 mg, 17.3 mg, 25.9 mg

Proven, Rapid Effectiveness for ADHD Patients 6-17 Years Old

- Only orally-disintegrating methylphenidate (MPH) tablet approved by FDA
- 61% improvement in ADHD symptoms at 1 hour (73% at 2 hours) over placebo
- 42% improvement in math performance over placebo
- Generic Concerta (MPH) also experiences drug shortages. Cotempla XR-ODT is an extended-release MPH tablet

Poly-Vi-Flor® Tri-Vi-Flor®

Multi-vitamin + fluoride supplement line containing novel L-methylfolate

- Most prescribed multivitamin + fluoride Rx brand in U.S.
- Provides a convenient, child friendly supplement for patients in non-fluoridated areas
- Only fluoride supplement containing Arcofolin®, a 'body ready' L-methylfolate enabling efficient folic acid metabolism

Rx Segment

Positive Adjusted EBITDA FY (June) 2023





See reconciliation of Adjusted EBITDA in Appendix

Aytu uses the term EBITDA, which is a term not defined under United States Generally Accepted Accounting Principles. The Company uses this term because it is a widely accepted financial indicator utilized to analyze and compare companies on the basis of operating performance. The Company believes that presenting EBITDA by segments allows investors to evaluate the various performance of these segments. The Company's method of computation of adjusted EBITDA may or may not be comparable to other similarly titled measures used by other companies. We believe that net loss is the performance measure calculated and presented in accordance with U.S. GAAP that is most directly comparable to EBITDA.

ADHD Market Dynamics

Since 2022, numerous Adderall XR and Concerta generic manufacturers reported ongoing, intermittent manufacturing delays contributing to supply shortages.

- Adzenys XR-ODT is FDA-approved as bioequivalent to Adderall XR and is the first and only orally disintegrating tablet (ODT) extended-release amphetamine. ODTs have a rapid onset, are easy to take, and help caregivers prevent “cheeking” or patient non-use of ADHD medications.
- ADHD is one of the most common developmental disorders in children and often persists into adulthood.
- In 2022, CDA reported that 6 million children in the United States ages 3 to 17 had previously received an ADHD diagnosis between 2016 and 2019, up 36% since 2003.
- In 2022, approximately 83.5 million prescriptions for ADHD medications were written in the United States and generated approximately $21.2 billion in sales.
- Extended-release, or long acting, dosage forms of stimulant medications are the standard of care for treating ADHD, making up approximately 43% of ADHD prescriptions.

Bloomberg

September 12, 2023

ADHD Drug Shortages Worsen as Makers Say Production Is Maxed Out

With supply constraints entering a second year, patients would like to see rules governing prescriptions loosened.

Aytu BIOPHARMA

Fluoride Market Dynamics

American Dental Association: Fluoride supplements can be prescribed for children ages 6 months to 16 years who are at high risk for tooth decay and whose primary drinking water contains low or no fluoride.

- Poly-Vi-Flor® and Tri-Vi-Flor® are two complementary prescription fluoride-based supplement product lines containing combinations of multiple vitamins and sodium fluoride in various oral formulations.
- While a majority of US drinking water is fluoridated, some major geographic areas including much of New Jersey and New York's Long Island lack it.
- Approximately 1 in 4 American children live in municipalities that do not fluoridate the water supply or in rural areas that rely on well water do not receive recommended levels of fluoride through fluoridation.
- In 2021, 9.5 million multi-vitamin prescriptions were written in the U.S. Of those prescriptions, multi-vitamins containing sodium fluoride accounted for 1.5 million total prescriptions.

Strong Prescription Growth Across Portfolio

Since FY 2020, the total prescriptions written monthly for both ADHD and Pediatric products have essentially doubled, supporting revenue trends.

ADHD Portfolio

26.1% Annual Growth



Pediatric Portfolio

29.6% Annual Growth



Aytu RxConnect Driving Rx Growth

Aytu RxConnect is a proprietary, best-in-class patient access program that enables affordable, predictable, hassle-free patient access to Aytu Rx products.

- ~1,000 pharmacies nationwide including independent pharmacies and two regional grocery chains
- Offers prescribers and patients affordability, predictability and access to Aytu brands for 100% of commercially insured
- Reduces pharmacy call backs relating to prior authorizations, step edits, and payor access barriers
- >90% of company scripts driven through RxConnect network

Novel Design Uniquely Serves Patients & HCPs



The Aytu RxConnect Platform Delivers Value for Patients, Prescribers, and Aytu

41% Reduction in Patient Out-of-Pocket Costs

2x Improvement in Aytu per Rx Contribution Margin

36% Increase in Rx Refills



Financial Summary

Revenue

11% YoY growth in Revenue driven by strength in Rx segment (21% YoY growth)



Positive Adjusted EBITDA in FY23

Aytu generated positive Adjusted EBITDA during 3 of its 4 quarters in FY 2023



See reconciliation of Adjusted EBITDA in Appendix

Aytu uses the term EBITDA, which is a term not defined under United States Generally Accepted Accounting Principles. The Company uses this term because it is a widely accepted financial indicator utilized to analyze and compare companies on the basis of operating performance. The Company believes that presenting EBITDA by segments allows investors to evaluate the various performance of these segments. The Company's method of computation of adjusted EBITDA may or may not be comparable to other similarly titled measures used by other companies. We believe that net loss is the performance measure calculated and presented in accordance with U.S. GAAP that is most directly comparable to EBITDA.

Quarterly Operating Expense

(excludes impairment and amortization of intangibles assets)`

Company focused on commercial leverage to drive growth while gaining operating efficiencies



- On October 13th, 2022, Aytu announced a strategic shift to focus corporate resources on Commercial Operations and indefinitely suspended all clinical development programs (Pipeline R&D).
  - Expected to save ≥ $20M in R&D expense over three years
- Tech transfer of Adzenys XR-ODT and Cotempla XR-ODT is expected to improve ADHD gross profit margins and eventually eliminate operating expenses associated with Grand Prairie, TX manufacturing facility.

Balance Sheet Highlights

(in thousands except shares outstanding)	6/30/2023
Cash and cash equivalents	$22,985
Total current assets	$72,832
Intangible assets, net	$58,970
Goodwill	$0
Total assets	$136,463
Total current liabilities	$69,015
Debt, net of current portion	$14,713
Total liabilities	$97,106
Total stockholders' equity	$39,357
Shares Outstanding	5,517,174
Shares, Warrants and Equity Awards Outstanding	12,112,951

Note held by Avenue Venture Opportunities Fund, L.P., interest only through 12/2024; matures 1/2025

Company expects to refinance note prior to maturity

Investment Highlights

Focus on sales growth, cost efficiencies, and positive cash flow

- Strong revenue growth over past 3 years driven by organic growth and strategic acquisitions driving $100M+ annualized run rate
- Company generated positive adjusted EBITDA in Fiscal 2023
- Positive industry dynamics in primary prescription markets (ADHD and Fluoride)
- ADHD manufacturing outsourcing initiative regulatory approvals moved forward and excess space has been subleased
- Innovative Aytu RxConnect can easily be leveraged to add additional products into platform
- Organic growth, platform leverage, macro dynamics and commercial focus should combine to allow the market to reappraise long-term opportunity and valuation

Appendix

Adjusted EBITDA Reconciliation

Aytu BioPharma, Inc.

Adjusted EBITDA Reconciliation

($ In Millions)

Consolidated

	FY 2021				FY 2022				FY 2023				Annual		
	Q1 Sep	Q2 Dec	Q3 Mar	Q4 Jun	Q1 Sep	Q2 Dec	Q3 Mar	Q4 Jun	Q1 Sep	Q2 Dec	Q3 Mar	Q4 Jun	FY21 Jun	FY22 Jun	FY23 Jun
	Actual	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*
Adjusted EBITDA Reconciliation															
Net income (loss)	(4.306)	(9.525)	(25.460)	(18.998)	(27.851)	(11.548)	(53.291)	(17.701)	(0.701)	(6.693)	(7.200)	(2.457)	(58.289)	(110.391)	(17.051)
Income tax (expense) benefit				0.259	(0.107)	(0.003)							0.259	(0.110)	
Depreciation & amort.	1.618	1.603	1.779	2.688	2.507	2.461	2.447	1.964	1.855	1.853	1.843	1.836	7.688	9.378	7.387
Impairment of goodwill/intangibles			4.286	8.539	19.453	0.000	45.196	10.809		2.600		5.224	12.825	75.458	7.824
Stock-based compensation expense	0.455	0.505	1.525	1.089	1.519	1.230	1.268	1.230	1.177	3.067	0.901	0.899	3.574	5.247	6.045
Other expense (income), net	0.738	0.366	0.407	0.399	0.005	(0.041)	0.032	0.762	1.084	1.228	1.215	1.252	1.910	0.758	4.779
Loss (gain) from contingent considerations	0.012	3.329	(0.617)	(7.043)	0.253	0.299	(1.234)	(0.974)	0.155	0.075	(0.734)	(0.465)	(4.319)	(1.656)	(0.969)
Gain on debt extinguishment		0.258		1.311			(0.169)					1.374	1.569	(0.169)	
Gain on derivative warrant liability							0.007		(2.191)	(1.403)	(2.573)			0.007	(4.793)
Adjusted EBITDA from cont operations	(1.483)	(3.464)	(18.080)	(11.756)	(4.221)	(7.602)	(5.744)	(3.910)	1.379	0.727	(6.548)	7.663	(34.783)	(21.478)	3.222

Adjusted EBITDA Reconciliation (Rx)

Aytu BioPharma, Inc.

Adjusted EBITDA Reconciliation

($ In Millions)

Rx Segment	FY 2021				FY 2022				FY 2023				Annual		
	Q1 Sep	Q2 Dec	Q3 Mar	Q4 Jun	Q1 Sep	Q2 Dec	Q3 Mar	Q4 Jun	Q1 Sep	Q2 Dec	Q3 Mar	Q4 Jun	FY21 Jun	FY22 Jun	FY23 Jun
	Actual	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*
Adjusted EBITDA Reconciliation															
Net income (loss)	(2.850)	(8.074)	(23.370)	(12.224)	(25.022)	(5.387)	(49.586)	(1.332)	1.001	(3.996)	(5.376)	3.677	(46.518)	(81.327)	(4.694)
Income tax (expense) benefit				0.259	(0.107)	(0.003)							0.259	(0.110)	
Depreciation & amort.	1.159	1.155	1.332	2.241	2.094	2.079	2.066	1.582	1.574	1.572	1.563	1.562	5.887	7.821	6.271
Impairment of goodwill/intangibles			4.286	8.539	19.453	0.000	45.196			2.600		0.130	12.825	64.649	2.730
Stock-based compensation expense	0.290	0.336	1.437	1.075	1.193	1.148	1.187	1.146	1.153	2.974	0.788	0.784	3.138	4.674	5.699
Other expense (income), net	0.686	0.320	0.401	0.395	0.006	(0.046)	0.017	0.750	1.073	1.217	1.229	1.205	1.802	0.727	4.724
Loss (gain) from contingent considerations	(0.002)	3.314	(0.632)	(7.139)	0.219	0.277	(1.257)	(0.999)	0.128	0.104	(0.345)	(0.465)	(4.459)	(1.760)	(0.578)
Loss (gain) on debt extinguishment		0.258		1.311			(0.169)						1.569	(0.169)	
Gain on derivative warrant liability							0.007		(2.191)	(1.403)	(2.573)	1.374		0.007	(4.793)
Adjusted EBITDA from cont operations	(0.717)	(2.691)	(16.546)	(5.543)	(2.164)	(1.932)	(2.539)	1.147	2.738	3.068	(4.714)	8.267	(25.497)	(5.488)	9.359

Adjusted EBITDA Reconciliation (Consumer Health)

Aytu BioPharma, Inc.

Adjusted EBITDA Reconciliation

($ In Millions)

Consumer Health Segment	FY 2021				FY 2022				FY 2023				Annual		
	Q1 Sep	Q2 Dec	Q3 Mar	Q4 Jun	Q1 Sep	Q2 Dec	Q3 Mar	Q4 Jun	Q1 Sep	Q2 Dec	Q3 Mar	Q4 Jun	FY21 Jun	FY22 Jun	FY23 Jun
	Actual	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*	*Actual*
Adjusted EBITDA Reconciliation															
Net income (loss)	(1.356)	(1.258)	(1.889)	(3.257)	(1.394)	(1.957)	(0.762)	(13.352)	(0.827)	(1.413)	(1.423)	(6.098)	(7.760)	(17.465)	(9.761)
Income tax (expense) benefit															
Depreciation & amort.	0.459	0.448	0.447	0.447	0.413	0.382	0.381	0.382	0.281	0.281	0.280	0.274	1.801	1.558	1.116
Impairment of goodwill/intangibles								10.809				5.094		10.809	5.094
Stock-based compensation expense	0.165	0.169	0.088	0.014	0.014	0.013	0.014	0.016	0.015	0.080	0.114	0.115	0.436	0.057	0.324
Other expense (income), net	0.052	0.046	0.006	0.004	(0.001)	0.005	0.015	0.012	0.011	0.011	(0.014)	0.047	0.108	0.031	0.055
Loss (gain) from contingent considerations	0.014	0.015	0.015	0.096	0.034	0.022	0.023	0.025	0.027	(0.029)	(0.389)		0.140	0.104	(0.391)
Gain on debt extinguishment															
Gain on derivative warrant liability															
Adjusted EBITDA from cont operations	(0.666)	(0.580)	(1.333)	(2.696)	(0.934)	(1.535)	(0.329)	(2.108)	(0.493)	(1.070)	(1.432)	(0.568)	(5.275)	(4.906)	(3.563)